| epirubicin / Generic mfg. |
| No Longer Available | N/A | | Europe | CEOP/IMVP-Dexa chemotherapy | Arbeitsgemeinschaft medikamentoese Tumortherapie | Lymphoma | | | | |
ChiCTR-TNC-09000363: A randomized, single blind controlled trial: transcatheter Arterial chemoembolization (TACE) of postoperative liver cancer by using three different drug. |
|
|
| Completed | N/A | 150 | | Epirubicin hydrochloride 40mg, iodine 5ml ;Genmzar 1000mg, iodine 5ml ;hydroxycamptothecia 10mg, iodine 5ml ;Epirubicin hydrochloride 40mg+Genmzar 1000mg, iodine 5ml ;Epirubicin hydrochloride 40mg+hydroxycamptothecia 10mg, iodine 5ml ;Genmzar 1000mg+hydroxycamptothecia 10mg, iodine 5ml | Eastern Hepatobiliary Surgery Hospital; Level of the institution：, self-financing | liver cancer | | | | |
ChiCTR-TRC-12002267: Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction：a clinical observation study |
|
|
| Completed | N/A | 60 | | Salidroside intervention+Epirubicin chemotherapy ;Epirubicin chemotherapy | Affiliated Jiangyin Hospital of Southeast University Medical College; Level of the institution：, Chinese Medical Project of Wuxi Health Science 2008(NO:ZXM0806) | Breast Cancer | | | | |
ChiCTR-TRC-11001319: Peri-operative chemotherapy with ECX (epirubicin + cisplatin + capecitabine) or XP (capecitabine + cisplatin) in the treatment of advanced gastric cancer: a randomized, multicenter, parallel control |
|
|
| Completed | N/A | 100 | | Preoperative chemotherapy of ECX for 3 cycles (Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2-4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4-6 weeks after surgery. ;Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2-4 weeks, and postoperative chemotherapy of XP for 3 cycles 4-6 weeks after surgery. | Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, Zhejiang Cancer Hospital | gastric cancer | | | | |
ChiCTR1800016150: A comparative study on the treatment of hepatocellular carcinoma (hepatocellular carcinoma) can not be resected by TACE combined with TACE |
|
|
| Recruiting | N/A | 50 | | Combination of epirubicin with drug loaded microspheres combined with ezumab | Hepatobiliary and pancreatic surgery in Affiliated Hospital of Qingdao University Medical College; Affiliated Hospital of Qingdao University Medical College, Jiangsu hengrui pharmaceutical co. LTD. | Primary hepatocellular carcinoma. | | | | |
ChiCTR-ONN-16010202: Comparative and multicenter study between Doxorubicin (Epirubicin\Pirarubicin)-eluting beads and conventional transarterial chemoembolization for treatment of advanced and unresectable hepatocellular carcinoma |
|
|
| Recruiting | N/A | 1000 | | Doxorubicin(Epirubicin\Pirarubicin)-eluting beads (CalliSpheres) TACE ;conventional (microspheres plus lipiodol-doxorubicin) TACE | The First Hospital Affiliated to Zhejiang University; The First Hospital Affiliated to Zhejiang University, Jiangsu Hengrui Medicine Co., LTD | Hepatocellular carcinoma | | | | |
ChiCTR1800019271: The feasibility of lidocaine-epirubicin-lipiodol emulsion in the pain management of chemoembolization for hepatocellular carcinoma: a prospective, open label, randomized, controlled trial |
|
|
| Recruiting | N/A | 70 | | Group A(n=35) received 100mg lidocaine(100mg,5ml) intraarterially immediately prior to TACE ;Group B(n=35) received lidocaine-epirubicin-lipiodol emulsion intraarterially during TACE (ratio of lidocaine-epirubicin solution to lipiodol 1:2, using 3-waystopcock). | Department of Radiology, the Second Xiangya Hospital of Central South University; Second Xiangya Hospital, At our own expense | Hepatocellular carcinoma (HCC) | | | | |
ChiCTR-IPR-17011503: A pilot randomized controlled trial evaluating pegylated liposomal doxorubicin (PLD) /cyclophosphamide (CTX) versus epirubicin/CTX as neoadjuvant therapy for operable breast cancer |
|
|
| Recruiting | N/A | 90 | | pegylated liposomal doxorubicin(PLD) 35 mg/m2 plus cyclophosphamide (CTX) 600 mg/m2, every 21 days for 4 cycles. ;epirubicin 90 mg/m2 plus cyclophosphamide (CTX) 600 mg/m2, every 21 days for 4 cycles. | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, sponsored by reserchers | Breast Cancer | | | | |
ChiCTR1900027545: Influence of cardiovascular risk factors on left ventricular wall motion and cardiac function in patients treated with epirubicin: a clinical study of layer-specific speckle tracking imaging |
|
|
| Not yet recruiting | N/A | 150 | | N/A | Department of Ultrasound Imaging, Renmin Hospital of Wuhan University; Renmin Hospital of Wuhan University, Fundamental Research Funds for the Central Universities (Grant Number: 2042017kf0155) | Patients with breast cancer under chemotherapy | | | | |
NCT03314532: The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 230 | RoW | TILA-TACE | Second Affiliated Hospital, School of Medicine, Zhejiang University | Surgical Resection, HCC | 12/20 | 12/22 | | |
NCT06323382: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 240 | RoW | Locoregional therapy, TACE/HAIC, Bevacizumab, Atezolizumab, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab | Sun Yat-sen University | Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab | 12/24 | 12/24 | | |
NCT06199297: Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma |
|
|
| Completed | N/A | 188 | RoW | Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy | Sun Yat-sen University | Hepatocellular Carcinoma | 07/23 | 07/23 | | |
NCT04619342: Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT) |
|
|
| Recruiting | N/A | 98 | RoW | GSMs-TACE, TACE, Surgical Resection | Beijing Tsinghua Chang Gung Hospital | Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT) | 06/21 | 12/22 | | |
ChiCTR1900028212: A multicenter, prospective, single-arm, exploratory clinical study of neoadjuvant therapy of her2-positive breast cancer with pyrotinib maleate tablets combined with paclitaxel for injection (albumin bound) |
|
|
| Recruiting | N/A | 90 | | pyrotinib maleate tablets combined with albumin paclitaxel combined with epirubicin and cyclophosphamide | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University, Self raise independently | breast cancer | | | | |
BL-PDT-RCT, NCT05547516: Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients |
|
|
| Not yet recruiting | N/A | 140 | RoW | Standard infusion chemotherapy, Standard infusion chemotherapy (including gemcitabine, mitomycin, Epirubicin, etc.), BL - 5 ala PDT, Blue laser-5ala Photodynamic therapy | First Affiliated Hospital Xi'an Jiaotong University | Non-muscle-invasive Bladder Cancer | 09/22 | 02/24 | | |
NCT05053386: Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 186 | RoW | Idarubicin Hydrochloride for Injection, Anbijian, Epirubicin, Epirubicin Hydrochloride | Zhejiang Cancer Hospital | Hepatocellular Carcinoma | 10/22 | 04/23 | | |
NCT04738188: Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria; |
|
|
| Recruiting | N/A | 226 | RoW | DEB-TACE, cTACE, Drug-eluting Beads, Epirubicin | Beijing Tsinghua Chang Gung Hospital | Hepatocellular Carcinoma | 11/22 | 12/25 | | |
NCT04582955: Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy |
|
|
| Recruiting | N/A | 20 | RoW | Chidamide in combination with chemotherapy, Other Name: For Chidamide: HBI-8000, CS055 | Tianjin Medical University Cancer Institute and Hospital | Triple-negative Breast Cancer | 12/22 | 12/22 | | |
NCT05146635: Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial |
|
|
| Recruiting | N/A | 110 | RoW | Intravesical Bcg, Intravesical chemotherapy (epirubicin) | Mansoura University | Bladder Cancer | 12/22 | 01/23 | | |
NCT06038552: The Long-term Efficacy of Imatinib With Hepatic Resection or Other Local Treatment for GIST Liver Metastases |
|
|
| Completed | N/A | 238 | RoW | imatinib (IM), Gleevec, hepatic resection (HR), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) | First Affiliated Hospital, Sun Yat-Sen University | GIST, Malignant, Liver Metastases | 12/22 | 05/23 | | |
PROTECT-06, NCT05128617: Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the Study |
|
|
| Completed | N/A | 20 | Europe | Epirubicin-cyclophosphamide, Epirubicin-endoxan, Paclitaxel, Taxol | Institut de cancérologie Strasbourg Europe, Université de Strasbourg - Unité de Recherche 3072 - Mitochondries, Stress oxydant, Protection musculaire | Breast Cancer | 05/23 | 05/23 | | |
ChiCTR2000033037: Interventional study of DC BeadTM epirubicin in the treatment of unreactable lung squamous cell carcinoma |
|
|
| Recruiting | N/A | 67 | | D-BACE +chemotherapy ;Chemotherapy ;DEB-BACE +chemotherapy | Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital, Self-collection | Squamous cell lung carcinoma | | | | |
ChiCTR2200058755: An exploratory single-arm clinical study of Lenvatinib combined with epirubicin in preoperative neoadjuvant therapy for locally advanced differentiated thyroid cancer |
|
|
| Not yet recruiting | N/A | 10 | | Lenvatinib combined with epirubicin | The Second Affiliated Hospital of Air Force Medical University; The Second Affiliated Hospital of Air Force Medical University, Chia Tai Tianqing Company | Thyroid Cancer | | | | |
ERI-Based-01, NCT05953909: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (). |
|
|
| Active, not recruiting | N/A | 120 | RoW | Eribulin-Based Regimen, Not Applicable since observational study, nab-paclitaxel based regimen, Other Chemotherapy Regimen | Fujian Cancer Hospital | Breast Cancer | 08/23 | 08/23 | | |
NCT04059003: CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer |
|
|
| Recruiting | N/A | 200 | RoW | Taxanes or/and anthracycline-based therapy | Shengjing Hospital | Breast Neoplasms | 08/23 | 08/24 | | |
ChiCTR2100051591: Clinical application study of superstable homogeneous mixture of iodinated oil and hydrophilic chemotherapy in improving the efficacy of TACE treatment for unresectable hepatocellular carcinoma |
|
|
| Not yet recruiting | N/A | 50 | | Innovative physical method for mixing iodide oil and epirubicin hydrochloride ;Traditional manual method for mixing iodide oil and epirubicin hydrochloride | Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Southwest Medical University, Outstanding Foundation of National Natural Science Foundation of China | Advanced unresectable hepatocellular carcinoma | | | | |
NCT05084586: Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation |
|
|
| Recruiting | N/A | 100 | RoW | Intravesical Solution, Continuous Epirubicin Instillation During the Early Postoperative Period, Single-Dose Epirubicin Instillation During the Early Postoperative Period | Ankara Training and Research Hospital | Bladder Cancer, Epirubicin Adverse Reaction, Superficial Bladder Cancer, Tumor Recurrence | 10/23 | 11/23 | | |
ChiCTR2000028961: Combination of high-throughput sequencing and primary cell culture as an exploratory study of individualized treatment of malignant tumors: phase 2 clinical trial of sintilimab for retroperitoneal dedifferentiation of liposarcoma |
|
|
| Not yet recruiting | N/A | 30 | | Neoadjuvant sintilimab monotherapy ;Neoadjuvant sintilimab combined with epirubicin and/or ifosfamide | Department of Urology, Shanghai Changhai Hospital, the Second Military Medical University, Shanghai, China; Second Military Medical University, Innovent Biologics, Inc. | retroperitoneal dedifferentiated liposarcoma | | | | |
ChiCTR2100047378: Prospective study of epirubicin loaded microspheres in the treatment of advanced prostate cancer |
|
|
| Recruiting | N/A | 30 | | CalliSpheres loaded with drug-loaded microspheres and epirubicin | Meizhou People's Hospital; Meizhou People's Hospital, Independent project | prostatic cancer | | | | |
EMEG-ECDD, NCT05296317: Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration |
|
|
| Recruiting | N/A | 100 | Europe | Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim), Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim) | Centre Georges Francois Leclerc | Localized Breast Cancer | 09/25 | 10/25 | | |
NCT05914753: Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer |
|
|
| Not yet recruiting | N/A | 200 | NA | Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel, Epirubicin, Cyclophosphamide, Docetaxel | Zhejiang Provincial People's Hospital | Breast Cancer, Chemotherapy Effect | 06/24 | 06/25 | | |
NCT04967482: DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC |
|
|
| Recruiting | N/A | 216 | RoW | Drug-eluting bead transarterial chemoembolization (DEB-TACE), Conventional transarterial chemoembolization (cTACE) | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 07/24 | 07/24 | | |
easy laugh, NCT05656079: To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study |
|
|
| Recruiting | N/A | 204 | RoW | Pegylated liposomal doxorubicin, duomeisu, Doxorubicin Hydrochloride Liposome Injection, Epirubicin, biaoroubixing, Cyclophosphamid, huanlinxianan, Trastuzumab, qutuozhudankang, Pertuzumab, patuozhudankang, Docetaxel, duoxitasai | Shanghai Pudong Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 09/24 | 09/25 | | |
NCT05661656: Catheter Guided Chemo-infusion in Breast Cancer |
|
|
| Not yet recruiting | N/A | 50 | NA | Intra-arterial chemoinfusion of breast cancer | Assiut University | Breast Cancer | 04/25 | 05/25 | | |
NCT05341141: Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy |
|
|
| Recruiting | N/A | 102 | RoW | Frozen glove and sock, ddEC-ddT, Chemotherapy | Peking University, CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 08/26 | 11/26 | | |
ChiCTR1900023776: A randomized, controlled, single-center clinical study for the efficacy and safety of docetaxel plus lobaplatin versus docetaxel plus epirubicin for neoadjuvant therapy in triple-negative breast cancer |
|
|
| Recruiting | N/A | 120 | | Docetaxel + Lobot ;Docetaxel + epirubicin | Southwest Hospital, Army Medical University; Southwest Hospital, Army Medical University, Self-raising | Triple negative breast cancer | | | | |
ChiCTR1900028438: A prospective, real-world clinical study for pegylated liposomal doxorubicin (PLD) versus epirubicin in the neoadjuvant treatment of HER-2 positive breast cancer |
|
|
| Not yet recruiting | N/A | 600 | | pegylated liposomal doxorubicin + cyclophosphamide sequential taxine + trastuzumab ± pertuzumab regimen ;epirubicin + cyclophosphamide sequential taxine + trastuzumab ± pertuzumab regimen | Sen Memorial Hospital, Sun Yat-Sen University; Sen Memorial Hospital, Sun Yat-Sen University, CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | | | | |
NCT05287308: Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study |
|
|
| Not yet recruiting | N/A | 500 | RoW | doxorubicin, epirubicin, pirarubicin, cyclophosphamide, albumin-bound paclitaxel, paclitaxel, docetaxel | Chinese Academy of Medical Sciences, CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 09/27 | 09/27 | | |
